Congratulations to all, especially Rockefeller's @veenapadmanaban.bsky.social, a research associate in
@sohailtavazoie.bsky.social's lab, and Maria Cecilia Campos Canesso, formerly a postdoc in @danmucida.bsky.social and @victora.bsky.social’s labs. A very well-deserved recognition!

Aprepitant use during chemotherapy and association with survival in women with early breast cancer AbstractBackground. Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary t

Clinically validates our work by @veenapadmanaban.bsky.social : neuronal substance P drives BrCA metastasis via tumor NK1R & is blocked by aprepitant. academic.oup.com/jnci/advance.... @rockefelleruniv.bsky.social @altnih4science.bsky.social @cancerneuroscience.bsky.social

🚨Women with ER(–) breast cancer who took aprepitant (anti-nausea drug, NK1R blocker) had a 31% lower risk of metastasis or death (p<0.001) in large Norwegian study by Botteri & Chang. More doses = better survival 📉.Clinically validates our our work by @veenapadmanaban.bsky.social

Fantastic work Cicca , Mucida and crew!!

Thanks Vijay!!

A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor Identifying patients at risk for metastatic relapse is a critical medical need. We identified a common missense germline variant in proprotein convert…

A commonly inherited genetic variant of human PCSK9 drives breast cancer metastasis and associates with reduced patient survival in @cellcellpress.bsky.social PCSK9 drives pro-metastatic gene expression by repressing LRP1. Anti-PCSK9 antibody suppresses Br mets.
sciencedirect.com/science/arti...